Abstract:Cystic fibrosis (CF) is a life‐limiting genetic condition, affecting over 90,000 people worldwide. CF affects several organs in the body, but airway damage has the most profound impact on quality of life (QoL) and survival. Causes of lower airway infection in people with CF are, most notably, Staphylococcus aureus in the early course of the disease and Pseudomonas aeruginosa at a later stage. Macrolide antibiotics, e.g. azithromycin and clarithromycin, are usually taken orally, have a broad spectrum of action against gram‐positive (e.g. S aureus ) and some gram‐negative bacteria (e.g. Haemophilus influenzae ), and may have a modifying role in diseases involving airway infection and inflammation such as CF. They are well‐tolerated and relatively inexpensive, but widespread use has resulted in the emergence of resistant bacteria. This is an updated review. To assess the potential effects of macrolide antibiotics on clinical status in terms of benefit and harm in people with CF. If benefit was demonstrated, we aimed to assess the optimal type, dose and duration of macrolide therapy. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearching relevant journals, and abstract books of conference proceedings. We last searched the Group's Cystic Fibrosis Trials Register on 2 November 2022. We last searched the trial registries WHO ICTRP and clinicaltrials.gov on 9 November 2022. We contacted investigators known to work in the field, previous authors and pharmaceutical companies manufacturing macrolide antibiotics for unpublished or follow‐up data, where possible. We included randomised controlled trials of macrolide antibiotics in adults and children with CF. We compared them to: placebo; another class of antibiotic; another macrolide antibiotic; or the same macrolide antibiotic at a different dose or type of administration. Two authors independently extracted data and assessed risk of bias. We assessed the certainty of evidence using GRADE. We included 14 studies (1467 participants) lasting 28 days to 36 months. All the studies assessed azithromycin: 11 compared oral azithromycin to placebo (1167 participants); one compared a high dose to a low dose (47 participants); one compared nebulised to oral azithromycin (45 participants); and one looked at weekly versus daily dose (208 participants). Oral azithromycin versus placebo There is a slight improvement in forced expiratory volume (FEV 1 % predicted) in one second in the azithromycin group at up to six months compared to placebo (mean difference (MD) 3.97, 95% confidence interval (CI) 1.74 to 6.19; high‐certainty evidence), although there is probably no difference at three months, (MD 2.70%, 95% CI ‐0.12 to 5.52), or 12 months (MD ‐0.13, 95% CI ‐4.96 to 4.70). Participants in the azithromycin group are probably at a decreased risk of pulmonary exacerbation with a longer time to exacerbation (hazard ratio (HR) 0.61, 95% CI 0.50 to 0.75; moderate‐certainty evidence). Mild side effects were common, but there was no difference between groups (moderate‐certainty evidence). There is no difference in hospital admissions at six months (odds ratio (OR) 0.61, 95% CI 0.36 to 1.04; high‐certainty evidence), or in new acquisition of P aeruginosa at 12 months (HR 1.00, 95% CI 0.64 to 1.55; moderate‐certainty evidence). High‐dose versus low‐dose azithromycin We are uncertain whether there is any difference in FEV 1 % predicted at six months between the two groups (no data available) or in the rate of exacerbations per child per month (MD ‐0.05 (95% CI ‐0.20 to 0.10)); very low‐certainty evidence for both outcomes. Only children were included in the study and the study did not report on any of our other clinically important outcomes. Nebulised azithromycin versus oral azithromycin We were unable to include any of the data into our analyses and have reported findings directly from the paper; we graded all evidence as being of very low certainty. The authors reported that there was a greater mean change in FEV 1 % predicted at one month in the nebulised azithromycin group (P < 0.001). We are uncertain whether there was a change in P aeruginosa count. Weekly azithromycin versus daily azithromycin There is probably a lower mean change in FEV 1 % predicted at six months in the weekly group compared to the daily group (MD ‐0.70, 95% CI ‐0.95 to ‐0.45) and probably also a longer period of time until first exacerbation in the weekly group (MD 17.30 days, 95% CI 4.32 days to 30.28 days). Gastrointestinal side effects are probably more common in the weekly group and there is likely no difference in admissions to hospital or QoL. We graded all evidence as moderate certainty. Azithromycin therapy i -Abstract Truncated-

Longitudinal lung function trajectories in response to azithromycin therapy for chronic lung disease in children with HIV infection: a secondary analysis of the BREATHE trial

Effect of antiretroviral therapy on longitudinal lung function trends in older children and adolescents with HIV-infection

Characterization of bacterial and viral pathogens in the respiratory tract of children with HIV-associated chronic lung disease: a case–control study

Long-Term Azithromycin Treatment in Pediatric Primary Ciliary Dyskinesia: A Retrospective Study

Bronchiectasis and other chronic lung diseases in adolescents living with HIV

Long-term pulmonary complications in perinatally HIV-infected youth

Prevalence, clinical presentation and factors associated with chronic lung disease among children and adolescents living with HIV in Kenya

Meta-Analysis of the Adverse Effects of Long-Term Azithromycin Use in Patients with Chronic Lung Diseases

The Lung Microbiome Predicts Mortality and Response to Azithromycin in Lung Transplant Patients with Chronic Rejection

Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection

Effect of Small Doses of Azithromycin on Pulmonary Ventilation Function and Inflammatory Factors IL-6, IL-13 in Children with Bronchial Asthma

Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe

Enhanced tuberculosis diagnosis with computer-aided chest X-ray and urine LAM in adults with HIV admitted to hospital (CASTLE study): A cluster randomised trial

Azithromycin alters spatial and temporal dynamics of airway microbiota in idiopathic pulmonary fibrosis

Macrolide antibiotics (including azithromycin) for cystic fibrosis

Lung function trajectories in children with early diagnosis of non-cystic fibrosis bronchiectasis: a retrospective observational study

Potential role of alveolar macrophages in HIV persistence and lung disease

Lung function in children with cystic fibrosis in the USA and UK: a comparative longitudinal analysis of national registry data

Weight and height z-scores improve after initiating ART among HIV-infected children in rural Zambia: a cohort study

The impact of HIV infection on skeletal maturity in peripubertal children in Zimbabwe: a cross-sectional study

[Potential role of alveolar macrophages in HIV persistence and lung disease]